Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 6/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.51 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.48 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13352075 | 0.94 | LPAR1 (0.57) | P2RY10LPAR1LPAR3GPR34PLA2G2C | |
| SCHEMBL12349096 | 0.94 | LPAR1 (0.57) | P2RY10LPAR1LPAR3GPR34PLA2G2C | |
| SCHEMBL12349100 | 0.92 | LPAR1 (0.57) | P2RY10LPAR1LPAR3PLA2G2CLPAR2 | |
| SCHEMBL12345737 | 0.91 | P2RY10 (0.59) | P2RY10LPAR1LPAR3GPR34PLA2G2C | |
| SCHEMBL12348908 | 0.91 | LPAR1 (0.51) | P2RY10LPAR1LPAR3GPR34PLA2G2C | |
| SCHEMBL10948714 | 0.86 | LPAR3 (0.63) | P2RY10LPAR1LPAR3PLA2G2CENPP2 | |
| SCHEMBL10948724 | 0.86 | LPAR3 (0.63) | P2RY10LPAR1LPAR3PLA2G2CENPP2 | |
| SCHEMBL10952127 | 0.86 | LPAR3 (0.63) | P2RY10LPAR1LPAR3PLA2G2CENPP2 | |
| SCHEMBL10952137 | 0.86 | LPAR3 (0.63) | P2RY10LPAR1LPAR3PLA2G2CENPP2 | |
| SCHEMBL12345666 | 0.84 | LPAR1 (0.64) | P2RY10LPAR1LPAR3GPR34PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
| WO-2010052718-A9 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | LPO, GPX4, ALOX15B | P2RY10 1977/4885LPAR1 305/4885LPAR3 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.